18,000 Shares in NewAmsterdam Pharma Company N.V. $NAMS Purchased by TD Asset Management Inc

TD Asset Management Inc bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the 3rd quarter, Holdings Channel reports. The firm bought 18,000 shares of the company’s stock, valued at approximately $512,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. lifted its position in shares of NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after acquiring an additional 490,656 shares during the period. Jennison Associates LLC grew its holdings in shares of NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after acquiring an additional 1,252,451 shares during the period. Adage Capital Partners GP L.L.C. increased its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Alliancebernstein L.P. increased its stake in NewAmsterdam Pharma by 4.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,331,583 shares of the company’s stock valued at $42,225,000 after purchasing an additional 89,630 shares in the last quarter. Finally, Maverick Capital Ltd. raised its holdings in NewAmsterdam Pharma by 178.8% during the second quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock worth $27,742,000 after purchasing an additional 982,405 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS opened at $29.86 on Friday. The business’s fifty day moving average price is $33.57 and its two-hundred day moving average price is $33.15. The stock has a market cap of $3.43 billion, a PE ratio of -17.26 and a beta of 0.04. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.92 million. As a group, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on NAMS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Wall Street Zen downgraded NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Needham & Company LLC boosted their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Guggenheim increased their price objective on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, The Goldman Sachs Group raised their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $47.10.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the completion of the sale, the chief accounting officer owned 24,353 shares in the company, valued at approximately $774,425.40. This trade represents a 57.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at $5,790,288. The trade was a 71.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 1,094,128 shares of company stock worth $37,170,889. 20.84% of the stock is owned by corporate insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.